대형 분자 의약품 원료 CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Large Molecule Drug Substance CDMO Market size is expected to reach USD 53.37 Billion in 2034 from USD 22.88 Billion (2025) growing at a CAGR of 9.87% during 2026-2034.

The Large Molecule Drug Substance Contract Development and Manufacturing Organization (CDMO) market is poised for significant expansion, driven by the increasing complexity of biologics and the growing demand for innovative therapies. As pharmaceutical companies pivot towards biologics, the need for specialized manufacturing capabilities becomes paramount. This market is characterized by a shift from traditional small-molecule drugs to large-molecule therapeutics, including monoclonal antibodies, recombinant proteins, and gene therapies. The intricate nature of these products necessitates advanced manufacturing processes, stringent quality control, and regulatory compliance, which CDMOs are uniquely positioned to provide.

Moreover, the rise of personalized medicine is catalyzing the demand for tailored biologic therapies, further propelling the growth of the Large Molecule Drug Substance CDMO market. As healthcare systems increasingly adopt precision medicine approaches, the ability to produce customized biologics at scale will be a critical differentiator for pharmaceutical companies. CDMOs that invest in cutting-edge technologies, such as single-use systems and continuous manufacturing, will likely gain a competitive edge. Additionally, strategic partnerships between biopharmaceutical companies and CDMOs will enhance innovation and expedite the development of novel therapies, ensuring that the market remains dynamic and responsive to emerging healthcare needs.

The global landscape for Large Molecule Drug Substance CDMOs is also influenced by regulatory advancements and the increasing focus on sustainability. As regulatory bodies streamline approval processes for biologics, the time-to-market for new therapies will decrease, fostering a more agile environment for CDMOs. Furthermore, the integration of sustainable practices in manufacturing processes will not only meet regulatory requirements but also align with the growing consumer demand for environmentally responsible healthcare solutions. As the market evolves, CDMOs that prioritize innovation, collaboration, and sustainability will be well-positioned to thrive in this burgeoning sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service

• Contract Manufacturing
• Contract Development

By Source

• Mammalian
• Microbial
• Others

By End-User

• Biotech Companies
• CRO
• Other

COMPANIES PROFILED

• Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent Inc, Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SERVICE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service
• 4.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Microbial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. CRO Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Service
  • 7.2.2 By Source
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Service
  • 7.3.2 By Source
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Service
  • 7.4.2 By Source
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Service
  • 7.5.2 By Source
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Service
  • 7.6.2 By Source
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Eurofins Scientific
  • 9.2.2 WuXi Biologics
  • 9.2.3 Samsung Biologics
  • 9.2.4 Catalent Inc
  • 9.2.5 Rentschler Biopharma SE
  • 9.2.6 AGC Biologics
  • 9.2.7 Recipharm AB
  • 9.2.8 Siegfried Holding AG
  • 9.2.9 Boehringer Ingelheim
  • 9.2.10 FUJIFILM Diosynth Biotechnologies